{"id":"NCT00321464","sponsor":"Amgen","briefTitle":"A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.","officialTitle":"A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (ZometaÂ®) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-04-01","primaryCompletion":"2009-07-20","completion":"2012-04-04","firstPosted":"2006-05-03","resultsPosted":"2014-03-10","lastUpdate":"2022-11-08"},"enrollment":2049,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Bone Metastases"],"interventions":[{"type":"BIOLOGICAL","name":"Denosumab","otherNames":[]},{"type":"DRUG","name":"Zoledronic Acid","otherNames":["Zometa"]}],"arms":[{"label":"zoledronic acid","type":"ACTIVE_COMPARATOR"},{"label":"denosumab","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone metastases in subjects with advanced breast cancer.","primaryOutcome":{"measure":"Time to First On-Study Skeletal Related Event (SRE) (Non-inferiority)","timeFrame":"Up to 34 months","effectByArm":[{"arm":"Zoledronic Acid","deltaMin":372,"sd":null},{"arm":"Denosumab","deltaMin":315,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["22951813","22893628","21060033","26335402","26093811","25976743","23975226","22975218"],"seeAlso":["http://download.veritasmedicine.com/REGFILES/amgen/Amgen_results_disclaimer.pdf","http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":471,"n":1013},"commonTop":["Nausea","Fatigue","Arthralgia","Back pain","Vomiting"]}}